MYB is reported to be amplified in ~10% of pancreatic tumor samples, and interestingly, its amplification was predominantly reported in advanced tumors indicating a strong correlation with the progression and malignant properties of pancreatic adenocarcinoma tumors [68]. This evidence concerns the gene MYB and pancreatic neoplasm.